Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
Down syndrome (DS) is a multi-faceted condition resulting in the most common genetic form of intellectual disability. Mouse models of DS, especially the Ts65Dn model, have been pivotal in furthering our understanding of the genetic, molecular and neurobiological mechanisms that underlie learning and memory impairments in DS. Cognitive and pharmacological insights from the Ts65Dn mouse model have led to remarkable translational progress in the development of therapeutic targets and in the emergence of DS clinical trials. Unravelling the pathogenic role of trisomic genes on human chromosome 21 and the genotype-phenotype relationship still remains a pertinent goal for tackling cognitive deficits in DS.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG, UK.
Aarti
A
Ruparelia
Matthew L
ML
Pearn
William C
WC
Mobley
D000818:Animals; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000150:complications* / Q000235:genetics; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D018696:Neuroprotective Agents / Q000627:therapeutic use*
D018696:Neuroprotective Agents